The platform is anchored in proprietary UBITh peptides, which are immunosilent, avoiding inflammation, and when linked to custom-designed target antigens, can elicit highly specific antibodies. The company aims to disrupt the treatment paradigm for chronic diseases dominated by drugs with prohibitive costs and cumbersome administration, leveraging its synthetic peptide vaccine platform to enable a new class of therapeutics that will improve quality, convenience, and access.
Cyborg Score Rationale
The company completed its IPO in November 2021 and has a differentiated synthetic peptide platform targeting large chronic disease markets. However, as of April 2026, the company has only 20 employees, indicating limited scale, and execution risk remains significant in bringing pipeline candidates through clinical trials.
Top Insights
Lead candidate UB-612 is a multitope peptide-based vaccine for COVID-19, with other candidates including UB-311 and Tau for Alzheimer's, UB-312 for Parkinson's, UB-313 for chronic migraine, and PCSK9 for hypercholesterolemia.
As of April 2026, the company operates with 20 employees, suggesting a lean R&D-focused organization with significant outsourcing or partnership dependencies.
Vaxxinity has raised $27M in funding, indicating modest capital for a public biotech with multiple pipeline programs.
Top competitors include Alector, Dynavax, and HOOKIPA Pharma.
Named Competitors
Alector — Immunotherapeutics for neurodegenerative diseases
Dynavax Technologies — Vaccine platform and immunotherapies